Capecitabine plus paclitaxel with sequential capecitabine alone as the firstline therapy in the treatment of recurrent and late gastric cancer.

Trial Profile

Capecitabine plus paclitaxel with sequential capecitabine alone as the firstline therapy in the treatment of recurrent and late gastric cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs Capecitabine (Primary) ; Paclitaxel
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 May 2012 Planned end date changed from 1 Dec 2007 to 31 Jul 2009 as reported by Chinese Clinical Trial Register.
    • 13 Apr 2012 Trial phase changed from II to I as reported by Chinese Clinical Trial Register record.
    • 24 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top